unwell and 3 days prior to resolution of symptoms, indicating their importance in 94 anti-viral immunity towards SARS-CoV-2. 95 96
Since co-expression of CD38 and HLA-DR is well defined as the key phenotype of 97 CD8 + T-cell activation towards viral infections, we analyzed activation of CD8 + T-98 cells by CD38/HLA-DR co-expression. In accordance with previous reports on Ebola 99 and influenza 1,4 , CD38 + HLA-DR + co-expression on CD8 + T-cells rapidly increased 100 from d7 (3.57%) to d8 (5.32%) and d9 (11.8%), with a decrease at d20 (7.05%) 101 (Fig.2b) . Furthermore, the frequency of CD38 + HLA-DR + co-expression on CD8 + T-102 cells in this patient was markedly higher than on CD8 + T-cells in healthy 103 individuals (1.47±0.50%, n=5). Similarly, CD38 + HLA-DR + co-expression increased 104 on CD4 + T-cells between d7 (0.55%) and d9 (3.33%) in the patient, compared to 105 healthy donors (0.63±0.28%, n=5), although at lower levels than CD8 + T-cells. 106 CD38 + HLA-DR + T cells, especially within CD8 + T-cells, produced higher amounts 107 of granzymes A/B and perforin (~34-54% higher) than their parent (CD8 + or CD4 + 108 populations, Fig.2b) . Thus, the emergence and rapid increase in activated 109 CD38 + HLA-DR + T-cells, especially CD8 + T-cells, at d7-9 preceded resolution of 110 symptoms. 111 112
We also analysed CD16 + CD14 + monocytes, related to immunopathology, and 113 activated HLA-DR + CD3 -CD56 + NK cells ( Fig.2c ). We detected reduced frequencies 114 of CD16 + CD14 + monocytes in peripheral blood at d7-9 (1.29%, 0.43%, 1.47%, 115 respectively), compared to healthy controls (9.03±4.39%, n=5). This might indicate 116 efflux of CD16 + CD14 + monocytes from blood to the site of infection, which remained 117 low at d20 (2.24%). Low levels of activated HLA-DR + CD3 -CD56 + NK cells were 118 found in both the COVID-19 patient and healthy controls. 119 120
As high levels of pro-inflammatory cytokines/chemokines are predictive of severe 121 clinical outcomes for influenza 5 , seventeen pro-inflammatory cytokines/chemokines 122 were quantified in patient's plasma. We found low levels of monocyte 123 chemoattractant protein-1 (MCP-1; CCL2), important for the recruitment of 124 monocytes, T-cells and dendritic cells to the site of infection ( Fig.2d ). However, these 125 MCP-1 levels were similar to healthy donors (22.15±13.81, n=5), patients infected 126 with influenza A (IAV) and influenza B viruses (IBV) at d7-9 (33.85±30.12, n=5) and 127 a patient with a known human coronavirus infection HCoV-229e (hCoV, 40.56). 128
Substantial levels of RANTES (CCL5), involved in homing and migration of 129
activated T-cells that express CCR5, were also detected in COVID-19 plasma but 130 these were comparable to healthy donors (p=0.412), IAV/IBV-infected patients 131 (p=0.310) and a hCoV-patient. Thus, in contrast to severe avian H7N9 disease with 132 highly elevated IL-6 and IL-8, and intermediate IL-10, MIP-1β, IFN-γ 5 , minimal pro-133 inflammatory cytokines/chemokines were found in this patient with CoVID-19, even 134 while symptomatic at d7-9. 135 136
Given that interferon-induced transmembrane protein-3 (IFITM3) single nucleotide 137 polymorphism (SNP)-rs12252-C/C was linked to severe influenza 5,6 , we analysed the 138 IFITM3-rs12252 SNP in this patient with COVID-19. Interestingly, the patient had 139
the 'risk' IFITM3-rs12252-C/C variant ( Fig.2e ), associated with clinical compromise 140 for 2009-pH1N1 6 and severe/fatal avian H7N9 disease 5 . As the relative prevalence of 141 IFITM3-rs12252-C/C risk variant in a healthy Chinese population is 26.5% (data 142 from 1,000 genome project) 5 , further investigations of the IFITM3-rs12252-C/C allele 143 in larger cohorts of patients with COVID-19 and its correlation with disease severity 144 is worth pursuing. 145 146
Collectively, our study provides novel contributions to the understanding of the 147 breadth of the immune response during a non-severe case of COVID-19. This patient 148 did not experience complications of respiratory failure, acute respiratory distress 149 syndrome, did not require supplemental oxygenation and was discharged within a 150
week of hospitalization, consistent with non-severe but clearly symptomatic disease. 151 We provide evidence on the recruitment of immune populations (antibody-secreting B 152 cells, follicular T-cells, activated CD4 + and CD8 + T-cells), together with IgM-IgG 153 SARS-CoV-2-binding antibodies, in patient's blood prior to resolution of clinical 154 symptoms. We propose that these immune parameters should be characterised in 155 larger cohorts of patients with COVID-19 with different disease severity to 156 understand whether they could be used to predict disease outcome and to evaluate 157 new interventions to minimise severity and/or to inform protective vaccine 158
candidates. Furthermore, our study indicates that robust multi-factorial immune 159 responses can be elicited towards the newly-emerged SARS- Cytokine analysis 297
Patient's plasma was diluted 1:4 before measuring cytokine levels (IL-2, IL-4, IL-6, 298
IL-8, IL-10, IL-12p70, IL-17A, IL-1β, IFN-α, MIP-1α, MIP-1β, MCP-1, 299 CD178/FasL, granzyme B, RANTES, TNF, IFN-γ) using the Human CBA Kit (BD 300
Biosciences, San Jose, California, USA). For RANTES, sera/plasma was also diluted 301 to 1:50. Healthy donors D6-D10 were of a mean age of 32 (range 22-55 years; 40% 302 females). 303 304
Whole blood staining and flow cytometry 305
Fresh whole blood (200μl per stain) was used to measure CD4 + CXCR5 + ICOS + PD1 + 306 follicular T cells (Tfh) and CD3 -CD19 + CD27 hi CD38 hi antibody-secreting B cell 307 (ASC; plasmablast) populations as described 3 as well as activated HLA-308 DR + CD38 + CD8 + and HLA-DR + CD38 + CD4 + T cells, inflammatory CD14 + CD16 + and 309 conventional CD14+ monocytes, activated HLA-DR + CD3 -CD56 + NK cells, as per the 310 specific antibody panels ( Supplementary Table 1 ; gating strategy is presented in
